Pharmacology and significance of nonsteroidal anti-inflammatory drugs in the treatment of skin diseases

Journal of the American Academy of Dermatology

Volumn 16, Issue 4, 1987, Pages 751-764

  Greaves, Malcolm W ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BENOXAPROFEN; BUFEXAMAC; DT0; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LIPOXYGENASE; LONAPALENE; MECLOFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PIROXICAM; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D1; PROSTAGLANDIN D2; PROSTAGLANDIN E1; PROSTAGLANDIN E2; SALICYLIC ACID; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; CLINICAL ARTICLE; DRUG COMPARISON; DRUG EFFICACY; DRUG MONITORING; DRUG STRUCTURE; HUMAN; PHARMACOKINETICS; PHARMACOLOGY; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN DISEASE; THERAPY; TOPICAL DRUG ADMINISTRATION; TREATMENT;

EID: 0023091213     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(87)70098-X     Document Type: Article

References (93)

1. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme
2. Hereditary angio-neurotic oedema: a clinical survey
3. Epsilon amino caproic acid (EACA) as a therapeutic agent. Based on 5 years' clinical experience
4. Treatment of hereditary angio-oedema
5. Cell calcium and contractile system regulation in arterial smooth muscle
6. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon
7. Acrodermatitis enteropathica: a lethal inherited human zinc-deficient disorder
8. The possible role of diodoquin as a zinc ionophore in the treatment of acrodermatitis enteropathica
9. The fatty acid composition of dermal and epidermal triglycerides and phosphatides in mouse skin during normal and abnormal growth
10. Sterols and keratinisation
11. 1-(3'-0 acyl) glycosyl-N-dihydroxypentatriacontadienoylsphingosine, a major component of the glucosyl ceramides of pig and human epidermis
12. How is the level of arachidonic acid controlled in mammalian cells?
13. Phospholipid methylation and biological signal transmission
14. Evidence that raised levels of phospholipase A2 in uninvolved epidermis of psoriasis are caused by hyperphosphorylation of an inhibitor
15. Biosynthesis and metabolism of prostaglandin E2 in human skin
16. Prostaglandin biosynthesis by human skin, and its inhibition by corticosteroids
17. Prostaglandin production by human epidermal cells in vitro. A model for studying pharmacological inhibition of prostaglandin synthesis
18. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets
19. Arachidonate lipoxygenase in human platelets
20. The identification of hydroxy fatty acids in psoriatic skin
21. The leukotrienes: a novel group of compounds including SRS-A and mediators of inflammation
22. Nomenclature for leukotrienes
23. The synthesis of leukotriene B4-like material by cultured human keratinocytes (abstract)
24. Release of lipoxygenase products of arachidonic acid from freshly isolated human keratinocytes
25. Synthesis of arachidonate lipoxygenase products by epidermal cells (abstract)
26. Inflammatory effects of prostaglandin D2 in rat and human skin
27. Effects of intravenous prostacyclin infusions in healthy volunteers&some preliminary observations
28. Oxygenation products of arachidonic acid as mediators of hypersensitivity and inflammation
29. Evidence in man of synergistic interaction between putative mediators of inflammation and asthma
30. Role of prostaglandin-mediated vasodilation in inflammation
31. Itch: the role of prostaglandins
32. Prostaglandins, aspirin-like drugs and analgesia
33. Prostaglandins and pruritus
34. Responses of human skin to intradermal injection of leukotrienes C4, D4 and B4
35. Production of intraepidermal microabscesses by topical application of leukotriene B4
36. Cutaneous responses to 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE)
37. 2 in epidermis of psoriasis
38. The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis
39. Topical clobetesol proprionate suppresses LTB4 in psoriasis (abstract)
40. Human allergic and irritant contact dermatitis; levels of arachidonic acid and its metabolites in involved skin
41. Increased concentrations of immunoreactive leukotrienes in cutaneous lesions of eosinophilic cellulitis
42. Lipoxygenase products of arachidonic acid in human inflamed skin
43. Recovery of prostaglandins in human cutaneous inflammation
44. Prostaglandin activity in human cutaneous inflammation: detection by radioimmunoassay
45. Increased concentrations of arachidonic acid, prostaglandins E2, D2 and 6-oxo-F1 and histamine in human skin following UVA-irradiation
46. Time course changes in levels of arachidonic acid and prostaglandin D2, E2 and F2 in human skin following ultraviolet B irradiation
47. Increased levels of 6-oxo-PGF1 in human skin following ultraviolet B irradiation
48. Irradiation of human skin by short wavelength ultraviolet radiation (100-290 nm) (UVC): increased con centrations of arachidonic acid and prostaglandins E2 and F2α
49. Increased production of prostaglandin D2 in patients with systemic mastocytosis
50. Raised levels of thromboxane B2 in systemic mastocytosis
51. Prostaglandin D2 and histamine release in cold urticaria (abstract)
52. Prostaglandin activity in sustained inflammation of human skin before and after aspirin
53. Effects of indomethacin on prostaglandins E2, F2α and arachidonic acid in human skin 24 h after UV-B and UV-C irradiation
54. The anti-inflammatory and pharmacological effects of topically applied flurbiprofen on human skin 24 hours after ultraviolet B irradiation
55. Lyosomal mechanisms of tissue injury and arthritis
56. Steroid anti-inflammatory drugs as inhibitors of phospholipase A2
57. Sodium cromoglycate and related drugs
58. Colchicine
59. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone
60. Biosynthesis of prostaglandin E2 in human skin: subcellular localisation and inhibition by unsaturated fatty acids and anti-inflammatory drugs
61. Aspirin selectivity inhibits prostaglandin production in human platelets
62. Some pharmacologic and biochemical aspects of prostaglandin biosynthesis and its inhibition
63. Differential inhibition of prostacyclin production and platelet aggregation by aspirin
64. Aspirin and ultraviolet light-induced erythema in man
65. Lack of covalent modification of prostaglandin synthetase (cyclooxygenase) by indomethacin
66. Arachidonate metabolism via lipooxygenase and 12L-hydroxperoxy 5,8,10,14-eicosatetraenoic acid peroxidase sensitive to anti-inflammatory drugs
67. Arachidonic acid and prostaglandin levels in dithranol erythema: time course study
68. Irritant reaction to dithranol in normal subjects and psoriasic patients
69. Factors influencing anthralin erythema
70. Pharma cological studies of anthralin erythema
71. The antiinflammatory and pharmacological effects of topically applied flurbiprofen on human skin 24 h after irradiation
72. The pharmacology of benoxaprofen (2-4-chlorophenyl-α-methyl-5-benzoxazole acetic acid) LRCL 3794, a new compound with anti-inflammatory activity apparently unrelated to inhibition of prostaglandin synthesis
73. Inhibition of rabbit PMN lipoxygenase activity by benoxaprofen
74. The preferential inhibition of 5-lipoxygenase product formation by benoxaprofen
75. Benoxaprofen: effect on cutaneous lesions of psoriasis
76. Benoxprofen improves psoriasis. A double-blind study
77. 5-lipoxygenase from human leucocytes [abstract]
78. A dimethoxynaphthalene derivative (RS043179 gel) compared with 0.025% fluocinolone acetonide gel in the treatment of psoriasis
79. Pharmacologic control of pruritus
80. Atopic dermatitis
81. Pruritus in polycythaemia vera; treatment with aspirin and possibility of platelet involvement
82. Secretory diarrhoea and prostaglandin D2 overproduction in mastocytosis
83. Topical indomethacin and sunburn
84. The therapeutic response of urticarial vasculitis to indomethacin
85. Delayed pressure urticaria
86. Urticarial vasculitis: a report of nine cases and review of the literature
87. Delayed pressure urticaria
88. Bufexemac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses
89. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer
90. Non-steroidal anti-inflammatory drugs: caution still indicated (editorial)
91. An expanded profile of cutaneous reactions to non-steroidal anti-inflammatory drugs